Testing for Human Papillomaviruses in Urine, Blood, and Oral Specimens: an Update for the Laboratory

Journal of Clinical Microbiology, Год журнала: 2023, Номер unknown

Опубликована: Июль 13, 2023

Twelve high-risk alpha human papillomavirus (HPV) genotypes cause approximately 690,000 cancer cases annually, with cervical and oropharyngeal being the two most prominent types. HPV testing is performed in laboratory settings for various applications of a clinical, epidemiological, research nature using range clinical specimens collected by clinicians or individuals (self-collected specimens).

Язык: Английский

---

The role of circulating viral and tumour DNA in the diagnosis and management of HPV associated anogenital cancers, a systematic review and meta-analysis

Journal of Clinical Virology, Год журнала: 2023, Номер 164, С. 105469 - 105469

Опубликована: Апрель 25, 2023

Human papillomavirus associated anogenital cancers are a significant global burden. The detection of biomarkers (circulating tumour DNA; ctDNA or circulating HPV cHPV DNA) in blood referred to as "liquid biopsy" may support the early diagnosis and monitoring affected individuals. A systematic review, including meta-analysis studies available literature on utilization DNA diagnostic, predictive, biomarker tests was performed following criteria PRISMA. total 31 were eligible for review; 20 used cervical cancers; 7 cancer; 5 anal no vulva, vaginal penile cancer available. identified low sensitivity (0.36) high specificity (0.96) diagnostic cancer. Comparatively, there (0.95) (1.0) and/or prognostic markers with poor clinical outcomes. Additionally, post treatment informative prediction response progression-free survival. promising disease. Evolution refinement molecular tools is likely improve performance further. Additionally comparative absence vulval, context warrants further exploration research.

Язык: Английский

---

The Evolving Landscape of Cervical Cancer: Breakthroughs in Screening and Therapy Through Integrating Biotechnology and Artificial Intelligence

Molecular Biotechnology, Год журнала: 2024, Номер unknown

Опубликована: Апрель 4, 2024

Язык: Английский

---

Curcuminoid PBPD induces cuproptosis and endoplasmic reticulum stress in cervical cancer via the Notch1/RBP‐J/NRF2/FDX1 pathway

Molecular Carcinogenesis, Год журнала: 2024, Номер 63(8), С. 1449 - 1466

Опубликована: Май 27, 2024

Abstract Curcumin has been shown to have antitumor properties, but its low potency and bioavailability limited clinical application. We designed a novel curcuminoid, [1‐propyl‐3,5‐bis(2‐bromobenzylidene)‐4‐piperidinone] (PBPD), which higher strength improves bioavailability. Cell counting kit‐8 was used detect cell activity. Transwell assay invasion migration ability. Western blot quantitative polymerase chain reaction were protein levels their messenger RNA expression. Immunofluorescence the location. PBPD significantly inhibited proliferation of cervical cancer cells, with an IC 50 value 4.16 μM for Hela cells 3.78 SiHa leading induction cuproptosis. Transcriptome sequencing analysis revealed that Notch1/Recombination Signal Binding Protein Immunoglobulin kappa J Region (RBP‐J) nuclear factor erythroid 2‐related 2 (NRF2) signaling pathways while upregulating ferredoxin 1 (FDX1) Knockdown Notch1 or RBP‐J NRF2 expression upregulated FDX1 expression, inhibition nicotinamide adenine dinucleotide phosphate activity oxidative stress, in turn activated endoplasmic reticulum stress induced death. The overexpression resulted enrichment within promoter region, thereby stimulating transcription. knockdown increase In addition, acidification tumor niche reduced metabolism inhibit migration. conclusion, inhibits proliferation, invasion, may be potential drug candidate treatment cancer.

Язык: Английский

---

Circulating Human Papillomavirus DNA Sequencing as a Biomarker of Response in Advanced Cervical Cancer

International Journal of Gynecological Cancer, Год журнала: 2025, Номер unknown, С. 101755 - 101755

Опубликована: Март 1, 2025

Despite intense multi-modal treatment, the prognosis for advanced cervical cancer remains poor. The recent increase in cases worldwide highlights an urgent need clinically validated biomarkers to guide patient management. Our pilot study investigates utility of human papillomavirus (HPV) circulating tumor deoxy ribonucleic acid (ctDNA) metastatic and recurrent cancer. We investigated association HPV ctDNA levels, early kinetics, detection viral-host integration sites with response outcomes. Serial plasma samples were prospectively collected from 21 patients metastatic/recurrent genotyping quantification conducted using a previously hybrid capture next-generation sequencing-based method. Mutation profiles within simultaneously bespoke panel. In addition, high-confidence was detected quantified SearcHPV. Differences progression-free survival overall also evaluated between at baseline those low or no-confidence Kaplan-Meier method log-rank tests compare groups. This cohort included HPV-associated Treatments front-line platinum-based chemotherapy without (n = 4) 5) bevacizumab, bevacizumab monotherapy 2), subsequent therapy 7). A total 3 treated kinetics during observation. At baseline, 20 (95.2%). From first assessment, change significantly associated type on treatment 18) (p .049) across all 21) .008). 26 unique mutations either tissue. Of these, 11 only plasma, 9 tissue, 6 Patients site have inferior compared low-confidence undetectable integration. this study, decrease mutation-based may application personalized should be larger studies.

Язык: Английский

---

Human papillomavirus 16 E6/E7 contributes to immune escape and progression of cervical cancer by regulating miR-142–5p/PD-L1 axis

Archives of Biochemistry and Biophysics, Год журнала: 2022, Номер 731, С. 109449 - 109449

Опубликована: Окт. 23, 2022

Язык: Английский

---

Cancer signature ensemble integrating cfDNA methylation, copy number, and fragmentation facilitates multi-cancer early detection

Experimental & Molecular Medicine, Год журнала: 2023, Номер 55(11), С. 2445 - 2460

Опубликована: Ноя. 1, 2023

Abstract Cell-free DNA (cfDNA) sequencing has demonstrated great potential for early cancer detection. However, most large-scale studies have focused only on either targeted methylation sites or whole-genome sequencing, limiting comprehensive analysis that integrates both epigenetic and genetic signatures. In this study, we present a platform enables simultaneous of methylation, copy number, fragmentomic patterns cfDNA in single assay. Using total 950 plasma (361 healthy 589 cancer) 240 tissue samples, demonstrate multifeature signature ensemble (CSE) classifier integrating all features outperforms single-feature classifiers. At 95.2% specificity, the detection sensitivity with models was 77.2%, 61.4%, 60.5%, respectively, but significantly increased to 88.9% CSE ( p value < 0.0001). For origin, enhanced accuracy beyond classifier, from 74.3% 76.4%. Overall, work proves utility information accurate

Язык: Английский

---

Detection of Multiple HPV Types in Liquid Biopsies of Cervical Neoplasia

Clinical Chemistry, Год журнала: 2024, Номер 70(1), С. 285 - 296

Опубликована: Янв. 1, 2024

Abstract Background More than 95% of cervical cancers and their precancerous lesions are caused by human papillomavirus (HPV). Cell-free (cf) HPV DNA detection in blood samples may serve as a monitoring tool for cancer. Methods In our methodological study, an panel simultaneous 24 types using mass spectrometry-based analysis was developed liquid biopsy approaches tested on positive cell lines, plasmid controls, high-grade squamous intraepithelial (HSIL) smear (n = 52). It validated cfDNA 40) cancer patients. Results The showed proficient results lines viral plasmids with limit 1 IU (international units)/µL HPV16/18 10GE/µL HPV11/31/33/39/45/51/52/58/59 specificity 100% the types. samples, detected sensitivity 98.14%. overall agreement between new clinical records 97.2% (κ 0.84). cfDNA, 26/40 (65.0%) any type, most infections due to hrHPV (24/26). were found all FIGO stages, highest positivity ratio III IV. Even lowest stage, I, had 12/23 (52.2%) patients plasma status. Conclusions This proof-of-concept paper shows that described assay produces reliable detecting multiplex high both cohorts. potential biopsy-based applications progression.

Язык: Английский

---

Sarcopenic Obesity in Cervical Carcinoma: A Strong and Independent Prognostic Factor beyond the Conventional Predictors (ESTHER Study—AFRAID Project)

Cancers, Год журнала: 2024, Номер 16(5), С. 929 - 929

Опубликована: Фев. 25, 2024

Locally advanced cervical cancer represents a significant treatment challenge. Body composition parameters such as body mass index, sarcopenia, and sarcopenic obesity, defined by sarcopenia BMI ≥ 30 kg/m

Язык: Английский

---

Combined Liquid Biopsy Methylation Analysis of CADM1 and MAL in Cervical Cancer Patients

Cancers, Год журнала: 2022, Номер 14(16), С. 3954 - 3954

Опубликована: Авг. 16, 2022

Cervical cancer is the fourth most common in women, which associated >95% with a high-risk human papillomavirus (HPV) infection. Methylation of specific genes has been closely progress cervical high-grade dysplastic lesions to invasive carcinomas. Therefore, DNA methylation proposed as triage for women infected HPV. analyses tissue have shown that cell adhesion molecule 1 (CADM1) and myelin lymphocyte protein (MAL) are present over 90% all neoplasias cancers. Here, we established liquid biopsy-based assay detect MAL CADM1 free (cf)DNA cancer. target gene was validated on bisulfite converted smear-DNA from dysplasia patients afterward applied cfDNA using quantitative real-time PCR. In 52 smears, combined analysis and/or (CADM1/MAL) showed 86.5% cases. samples 24 patients, CADM1/MAL detected 83.3% already 81.8% stage I-II showing high sensitivity this biopsy assay. combination specificity 95.5% towards healthy donors (HD) an area under curve (AUC) 0.872 receiver operating characteristic (ROC) analysis, detection might represent novel promising marker

Язык: Английский

---